| Literature DB >> 30116153 |
M Ben Jmaa1, O Abida1, R Fakhfakh1, E Bahloul2, Kh Sellami2, L Gaddour3, N Elloumi1, M Ben Ayed1, A Masmoudi2, M Dhouib4, M Abdelmoula4, N Mahfoudh3, H Makni3, H Turki2, H Masmoudi1.
Abstract
Pemphigus foliaceus (PF) is a rare autoimmune skin disease caused by anti-Dsg1 pathogenic autoantibodies. It is considered as a Th2-mediated disease. Likewise, Th17 cells were recently described in the pathogenesis of the disease but their role is still unclear. We aimed to unravel the eventual implication of the IL23/Th17 pathway in the development of PF. A case-control study was conducted on 115 PF patients and 201 healthy controls using PCR-RFLP and AS-PCR methods. SNPs in IL23R, RORγt, IL17A, IL17F, IL17AR, TNFa, and STAT3 genes were genotyped. mRNA expression of IL23R and RORγt was evaluated using Q-PCR. The frequency of circulating Th17 cells was analyzed by flow cytometry. Genetic associations between IL23R>rs11209026, IL17A>rs3748067, IL17F>rs763780, and TNFa>rs1800629 and the susceptibility to PF were reported. Moreover, we revealed a significant increased frequency of circulating CD4+IL17+ cells as well as higher mRNA levels of RORγt and IL23R in PBMCs of patients. However, no significant increase of RORγt and IL23R mRNA expression was observed in lesional skin biopsies. In spite of the little size of specimens, our results provide converging arguments for the contribution of the IL23/Th17 pathway in the pathogenesis of PF.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30116153 PMCID: PMC6079402 DOI: 10.1155/2018/8206983
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Characteristics of study populations.
| Features | PF patients | Controls |
|---|---|---|
| Number | 115 | 201 |
| Sex ratio | 1/14 | 1/9 |
| Mean age | 35 (18–84) | 39 (14–73) |
| Origin | Center-southern regions of Tunisia | |
| Anti-Dsg1 | Positive | Negative |
Primary information of genotyped SNPs in Th17/IL23 pathway's genes.
| Gene | Base change | MAF | Chromosome regions | Localization | Primers | Enzyme |
|---|---|---|---|---|---|---|
| IL23R | G/T | 0.47 | Chr1 | Exon2 | F:Fam✪ TGCTCTGTTTCCTTCCTTCC |
|
| IL23R | G/T | 0.36 | Intron6 | F:ATTTCTGGATGCCCTTTCCT | BbvI | |
| IL23R | A/G | 0.022 | Exon8 | F:TTAGACAACAGAGGAGACATTGGA | Hpy188I | |
| IL23R | A/C | 0.39 | 3′UTR | F:TGCTGGGCCATATGATAAGC | MnII | |
| ROR | T/C | Chr1 | Intron | F1:T4CCTCACAGCAAATCTTTTCTC | — | |
| IL17A | A/G | 0.29 | Chr6 | 5′UTR | F:ATTTCTGCCCTTCCCATTTT | EarI |
| IL17A | T/C | 0.077 | 3′UTR | R:GGGGCGAAAATGGTTACGAT | ApoI | |
| IL17F | C/T | 0.093 | Chr6 | Exon3 | F:TGGGTAAGGAGTGGCATTTC | NlaIII |
| IL17RA | G/A | 0.233 | Chr22 | 5′UTR | F:TGAAATGTGTAATTCGCTGGC | PvuII |
| TNF | A/G | 0.090 | Chr6 | 5′UTR | F:AGGCAATAGGTTTTGAGGGGCAT | NcoI |
| STAT3 | C/T | 0.482 | Chr17 | Intron | F:GCTGGAGTACAAACCCTGAA | AluI |
aGenotyped using the AS-PCR method.
Genotype and allele frequencies of IL23/Th17 pathway's genes polymorphisms in Pemphigus foliaceus patients and matched healthy controls.
| Gene/SNP | Genotype/allele | Case | Control |
| OR | 95% CI |
|---|---|---|---|---|---|---|
| IL23R | AA | 0 | 5 (2.6) | NS | — | — |
| AG | 11 (10.3) | 41 (21.2) | 0.016 | 0.42 | 0.21–0.87 | |
| GG | 96 (89.7) | 147 (76.2) | 0.004 | 2.37 | 1.35–5.53 | |
| A | 11 (5.1) | 51 (13.2) | 0.001 | 0.35 | 0.18–0.69 | |
| G | 203 (94.9) | 335 (86.8) | ||||
|
| ||||||
| IL23R | GG | 3 (3) | 11 (8.3) | NS | — | — |
| GT | 80 (79.2) | 106 (79.7) | NS | — | — | |
| TT | 18 (17.8) | 16 (12) | NS | — | — | |
| G | 86 (42.6) | 128 (48.1) | NS | — | — | |
| T | 116 (57.4) | 138 (51.9) | ||||
|
| ||||||
| IL23R | GG | 10 (9.8) | 14 (7.4) | NS | — | — |
| GT | 43 (42.2) | 75 (39.7) | NS | — | — | |
| TT | 49 (48) | 100 (52.9) | NS | — | — | |
| G | 63 (30.9) | 103 (27.2) | NS | — | — | |
| T | 141 (69.1) | 276 (72.8) | ||||
|
| ||||||
| IL23R | AA | 20 (19.8) | 40 (22.1) | NS | — | — |
| AC | 41 (40.6) | 71 (39.2) | NS | — | — | |
| CC | 40 (39.6) | 70 (38.7) | NS | — | — | |
| A | 81 (40.1) | 151 (41.7) | NS | — | — | |
| C | 121 (59.9) | 211 (58.3) | ||||
|
| ||||||
| IL17A | AA | 1 (1) | 1 (0.6) | NS | — | — |
| AG | 9 (9.2) | 10 (6.2) | NS | — | — | |
| GG | 88 (89.8) | 150 (93.2) | NS | — | — | |
| A | 11 (5.6) | 12 (3.7) | NS | — | — | |
| G | 185 (94.4) | 310 (96.3) | ||||
|
| ||||||
| IL17A | TT | 0 | 4 (3.6) | NS | — | — |
| CT | 10 (11.1) | 38 (35) | 9.47 | 0.23 | 0.11–0.50 | |
| CC | 79 (87.7) | 66 (60.8) | 1.17 | 5.03 | 2.34–10.78 | |
| T | 10 (5.5) | 46 (21.1) | 8.29 | 0.218 | 0.10–0.44 | |
| C | 170 (94.4) | 171 (78.8) | ||||
|
| ||||||
| IL17AR | AA | 78 (74.3) | 137 (71.8) | NS | — | — |
| AG | 24 (22.9) | 48 (25.1) | NS | — | — | |
| GG | 3 (2.9) | 6 (3.1) | NS | — | — | |
| A | 180 (85.7) | 322 (84.3) | NS | — | — | |
| G | 30 (14.3) | 60 (15.7) | ||||
|
| ||||||
| IL17F | CC | 5 (4.7) | 3 (1.6) | NS | — | — |
| CT | 13 (12.3) | 13 (6.7) | NS | — | — | |
| TT | 88 (83) | 177 (91.7) | 0.02 | 0.44 | 0.22–0.91 | |
| C | 23 (10.8) | 19 (4.9) | 0.007 | 2.35 | 1.24–4.42 | |
| T | 189 (89.2) | 367 (95.1) | ||||
|
| ||||||
| TNFa | AA | 12 (12.8) | 9 (5) | 0.022 | 2.76 | 1.12–6.82 |
| AG | 37 (39.4) | 43 (24) | 0.008 | 2.05 | 1.20–3.51 | |
| GG | 45 (47.9) | 127 (70.9) | 0.0002 | 0.38 | 0.22–0.63 | |
| A | 61 (32.4) | 61 (17) | 4.06 | 2.33 | 1.55–3.52 | |
| G | 127 (67.6) | 297 (83) | ||||
|
| ||||||
| ROR | TT | 0 | 0 | NS | — | — |
| CT | 9 (7.9) | 13 (6.5) | NS | — | — | |
| CC | 106 (92.1) | 188 (93.5) | NS | — | — | |
| T | 11 (4.7) | 13 (3.3) | NS | — | — | |
| C | 219 (95.3) | 389 (96.7) | NS | — | — | |
|
| ||||||
| STAT3 | TT | 22 (23.1) | 29 (18.1) | NS | — | — |
| CT | 47 (49.5) | 77 (48.1) | NS | — | — | |
| CC | 26 (27.4) | 54 (33.8) | NS | — | — | |
| T | 91 (47.9) | 135 (42.2) | NS | — | — | |
| C | 99 (52.1) | 185 (57.8) | NS | — | — | |
Figure 1Overview and linkage disequilibrium (LD) on chromosome 1q31.1. (a) Overview of chromosome 1. (b) Schematic structure of the IL23R gene. Exons are depicted by black vertical lines. The positions of the four SNPs are shown by the arrows. (c) LD prime charts generated using SHEsis software summarize LD (D') patterns between the 4 SNP. D' > 0.7 is considered as a high value of LD.
Haplotypes of genotyped SNPs on chromosomes 1 and 6.
| Chromosome | Haplotype | Case | Control |
| OR (95% CI) |
|---|---|---|---|---|---|
| 1 | TTGA | 44 (23.4) | 39 (16.3) | 1.71 | 2.409 (1.508~3.846) |
| TGGC | 33 (17.5) | 24 (10) | 1.16 | 2.871 (1.648~5.001) | |
| 6 | AGGT | 42 (0.291) | 30(0.168) | 7.67 | 3.027 (1.832~5.003) |
| GGAT | 6 (0.041) | 38 (0.213) | 0.002 | 0.276 (0.114~0.664) |
Figure 2Overview and linkage disequilibrium (LD) on chromosome 6. (a) Overview of chromosome 6. (b) Schematic structure of the IL17A, IL17F, and TNFa genes. The positions of the four SNPs are shown by the arrows (c). LD prime charts generated using SHEsis software summarize LD (D') patterns between the 4 SNPs. D' > 0.7 is considered as a high value of LD.
Combinations of genotyped SNPs in IL23R, IL17A, IL17F, TNFa, RORγt, and STAT3 showing significant differences between PF patients and controls.
| Combinations | Case | Control |
| OR (95% CI) |
|---|---|---|---|---|
| TTGAAGCTAC | 7 (5.5) | 3 (2.3) | 0.018 | 4.497 (1.151~17.574) |
| TGGCGGCTAC | 10 (7.9) | 4 (3.1) | 0.003 | 4.877 (1.511~15.742) |
| TTGAGGCTAT | 11 (8.7) | 7 (5.4) | 0.017 | 3.057 (1.167~8.006) |
Figure 3mRNA expression of IL23R and RORγt in peripheral blood (a) and skin biopsies (b). PBMCs were extracted from 5 de novo patients and 4 HC. Biopsies from de novo patients (N = 10), patients in the chronic stage (N = 3), and from HC (N = 5) were analyzed using Q-PCR. The relative expression was estimated using 2−ΔΔCt method and normalized to the average of the GAPDH housekeeping gene. P value was calculated using Mann–Whitney U test.
Figure 4Frequency of IL17+ cells in the peripheral blood mononuclear cells of PF patients and healthy controls. Th17 cells identified using specific antibodies CD4-PerCP-Cy5 and IL17A-PE. Representative flow cytometry analysis of Th17 cells in healthy controls (a, b) and in PF patients (c, d). (e) Percentage of Th17 cells in control and patients' PBMCs.